Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab in combination with carfilzomib, lenalidomide and dexamethasone (E-KRd) versus KRd around autologous stem cell transplant and maintenance with elotuzumab + lenalidomide versus lenalidomide alone in newly diagnosed multiple myeloma
2017-001616-11Phase 3Active
- Sponsor
- University Hospital Würzburg
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of elotuzumab in multiple myeloma (MM) (2 arms), sponsored by University Hospital Würzburg. Primary endpoints: VGPR or better response rate and Long-term efficacy. Started Dec 2017; status: active.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-001616-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001616-11.